Literature DB >> 24307696

The impact of miRNA-based molecular diagnostics and treatment of NRF2-stabilized tumors.

Shinsuke Yamamoto1, Jun Inoue, Tatsuyuki Kawano, Ken-ichi Kozaki, Ken Omura, Johji Inazawa.   

Abstract

UNLABELLED: NF-E2-related factor 2 (NRF2) is a master transcriptional regulator that integrates cellular stress responses and is negatively regulated by Kelch-like ECH-associated protein 1 (KEAP1) at the posttranslational level. In human cancers, aberrantly stabilized NRF2, either by mutation of NRF2 or KEAP1, plays a vital role in chemoresistance and tumor cell growth through the transcriptional activation of target genes, suggesting that targeted inhibition of NRF2 is a potential therapy for NRF2-stabilized tumors. MicroRNAs (miRNA) are endogenous small noncoding RNAs that can negatively regulate gene expression by interfering with the translation or stability of target transcripts. Moreover, tumor-suppressor miRNAs have been suggested to be useful for cancer treatment. Here, a reporter-coupled miRNA library screen identified four miRNAs (miR-507, -634, -450a, and -129-5p) that negatively regulate the NRF2-mediated oncogenic pathway by directly targeting NRF2. Importantly, downregulation of these miRNAs, in addition to the somatic mutation of NRF2 or KEAP1, is associated with stabilized NRF2 and poor prognosis in esophageal squamous cell carcinoma (ESCC). Furthermore, administration of a miR-507 alone or in combination with cisplatin inhibited tumor growth in vivo. Thus, these findings reveal that miRNA-based therapy is effective against NRF2-stabilized ESCC tumors. IMPLICATIONS: This study determines the potential of miRNA-based molecular diagnostics and therapeutics in NRF2-stablized tumors. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24307696     DOI: 10.1158/1541-7786.MCR-13-0246-T

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  30 in total

Review 1.  MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy.

Authors:  Ai-Ming Yu; Ye Tian; Mei-Juan Tu; Pui Yan Ho; Joseph L Jilek
Journal:  Drug Metab Dispos       Date:  2015-11-13       Impact factor: 3.922

2.  MiR-634 sensitizes nasopharyngeal carcinoma cells to paclitaxel and inhibits cell growth both in vitro and in vivo.

Authors:  Xiaowei Peng; Peiguo Cao; Dong He; Shuang Han; Jianda Zhou; Guolin Tan; Wei Li; Fenghui Yu; Jianjun Yu; Zan Li; Ke Cao
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

Review 3.  MicroRNAs and Corresponding Targets in Esophageal Cancer as Shown In Vitro and In Vivo in Preclinical Models.

Authors:  Ulrich H Weidle; Adam Nopora
Journal:  Cancer Genomics Proteomics       Date:  2022 Mar-Apr       Impact factor: 4.069

Review 4.  Regulation of ferroptosis by noncoding RNAs: a novel promise treatment in esophageal squamous cell carcinoma.

Authors:  Guanen Qiao; Wenjuan Zhang; Kui Dong
Journal:  Mol Cell Biochem       Date:  2022-04-21       Impact factor: 3.842

Review 5.  Targeted therapy of esophageal squamous cell carcinoma: the NRF2 signaling pathway as target.

Authors:  Shaohua Ma; Chorlada Paiboonrungruan; Tiansheng Yan; Kevin P Williams; M Ben Major; Xiaoxin Luke Chen
Journal:  Ann N Y Acad Sci       Date:  2018-05-11       Impact factor: 5.691

6.  NRF2/ACSS2 axis mediates the metabolic effect of alcohol drinking on esophageal squamous cell carcinoma.

Authors:  Joab Otieno Odera; Zhaohui Xiong; Caizhi Huang; Ning Gu; Wenjun Yang; Jessie Githang'a; Elizabeth Odera; Chorlada Paiboonrungruang; Xiaoxin Chen
Journal:  Biochem J       Date:  2020-08-28       Impact factor: 3.857

7.  LncRNA UCA1-miR-507-FOXM1 axis is involved in cell proliferation, invasion and G0/G1 cell cycle arrest in melanoma.

Authors:  Yanping Wei; Qianqian Sun; Lindong Zhao; Jianbo Wu; Xiaonan Chen; Yuanyuan Wang; Wenqiao Zang; Guoqiang Zhao
Journal:  Med Oncol       Date:  2016-07-07       Impact factor: 3.064

Review 8.  Cancer-associated miRNAs and their therapeutic potential.

Authors:  Jun Inoue; Johji Inazawa
Journal:  J Hum Genet       Date:  2021-06-04       Impact factor: 3.172

Review 9.  Nrf2 as a potential target for Parkinson's disease therapy.

Authors:  Yingcai Niu; Jing Zhang; Miaoxian Dong
Journal:  J Mol Med (Berl)       Date:  2021-04-12       Impact factor: 4.599

Review 10.  Cytoprotection "gone astray": Nrf2 and its role in cancer.

Authors:  Claudia Geismann; Alexander Arlt; Susanne Sebens; Heiner Schäfer
Journal:  Onco Targets Ther       Date:  2014-08-26       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.